

Bibliography for ViiV Healthcare Product Pipeline – Binding and Fusion Stage

Summary

- The ViiV Healthcare product pipeline includes three areas of focus: ultra long-acting medications for treatment of HIV, ultra long-acting medications for HIV pre-exposure prophylaxis (PrEP), and self-administered HIV treatment options.
 - The following citations are relevant to products currently in development that target the binding & fusion stage of the HIV life cycle. Citations are listed alphabetically.

BINDING AND FUSION

N6LS (VH3810109, bNAb)

Edwards AY, et al. Pharmacokinetics/Pharmacodynamics and virological activity of VH3810109 (N6LS) in antiretroviral-naïve viremic adults from the phase IIa BANNER study. Presented at the 19th European AIDS Conference (EACS), October 18-21, 2023, Warsaw, Poland. [ePoster](#). ([poster+audio](#))

Edwards AY, et al. Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study. Presented at the 20th European AIDS Conference (EACS), October 15-18, 2025, Paris, France. Moderated ePoster. ([poster](#)) ([Plain Language Summary](#))

Ferris R, et al. Temsavir Treatment Enhances bnAb Recognition and Subsequent Clearance of HIV-1 Infected Cells. Presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2024, Denver, Colorado. [Poster 374](#).

Ferris R, et al. Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs). Presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI), March 9-12, 2025, San Francisco, California. [Poster 507](#).

Gartland M, et al. Correlation of baseline phenotypic sensitivity with virological response to VH3810109 (N6LS) in BANNER. Presented at HIV Glasgow 2024, November 10-13, 2024, Glasgow, UK. [Poster P037](#).

Gartland M, et al. Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study. Presented at the 20th European AIDS Conference (EACS), October 15-18, 2025, Paris, France. ePoster. ([poster](#)) ([Plain Language Summary](#))

Griesel R, et al. Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study. Presented at the 20th European AIDS Conference (EACS), October 15-18, 2025, Paris, France. Parallel Session. ([poster](#)) ([Plain Language Summary](#))

Gutner CA, et al. Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives. Presented at the 20th European AIDS Conference (EACS), October 15-18, 2025, Paris, France. ePoster. ([poster](#)) ([Plain Language Summary](#))

Huang J, Kang BH, Ishida E, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. *Immunity*. 2016;45(5):1108-1121. doi:<http://dx.doi.org/10.1016/j.immuni.2016.10.027>.

Keegan M, et al. VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models. Presented at HIV Glasgow 2024, November 10-13, 2024, Glasgow, UK. [Poster P208](#).

Leone P, et al. The Clinical Development of VH3810109 (N6LS): Advancing Ultra-Long-Acting HIV Treatment into the Future. Presented at IDWeek 2025, October 19-22, 2025, Atlanta, Georgia. Poster 380. ([poster](#)) ([Plain Language Summary](#))

Leone P, et al. Impact of Baseline Factors on Virologic Response to BNAB VH3810109 (N6LS) in BANNER. Presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), February 19-22, 2023, Seattle, Washington. [Poster](#).

Leone P, et al. Safety and tolerability of VH3810109 (N6LS) among antiretroviral therapy-naïve adults living with HIV-1: results from the monotherapy phase of the phase IIa BANNER study. Presented at the 19th European AIDS Conference (EACS), October 18-21, 2023, Warsaw, Poland. [Oral presentation in parallel session](#).

Leone P, et al. VH3810109 (N6LS) in Antiretroviral Therapy-Naïve Adults With HIV-1: Phase IIa BANNER Efficacy Data. Presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2024, Denver, Colorado. [Oral presentation](#).

Leone P, et al. VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive adults living with HIV: proof of concept achieved in the phase IIa BANNER (207959, NCT04871113) study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually. [Oral Presentation](#).

Taiwo B, et al. VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study. Presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI), March 9-12, 2025, San Francisco, California. Oral presentation. ([slides with Plain Language Summary](#))

Wensel D, et al. Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb. Presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI), March 9-12, 2025, San Francisco, California. [Poster](#).

Widge A, et al. Phase I dose-escalation study of human monoclonal antibody N6LS in healthy adults. Presented at the Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020, Boston, MA, USA. [Poster 508](#).

Win B, et al. High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase I SPAN Study Safety Results. Presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2024, Denver, Colorado. [Poster](#).

Wu R, et al. N6LS with RHUPH20 enables safe high dose monoclonal antibody subcutaneous delivery. Presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), February 19-22, 2023, Seattle, Washington. [Poster 499](#).



Scan QR Code to access and download complete Pipeline Bibliography

This information is scientific and non-promotional in nature and is not intended for further distribution. These products have not been approved by the FDA; therefore, no conclusions should be drawn about the safety or efficacy of these products. Selection of references follows principles of evidence-based medicine and, therefore, references may not be all inclusive.